

**18 December 2020**

**Bould Opportunities plc**

("Bould Opportunities" or the "Company")

**Corporate Update**

Bould Opportunities is pleased to provide an update to shareholders.

As announced on 8 April 2020, the Company, together with its various professional advisers, is working to complete the acquisition of a company focussed on early cancer detection (the "Proposed Transaction"). The Directors appreciate the concerns of shareholders regarding the continuing delay in completing the Proposed Transaction. This has primarily been a result of the painstaking process of listing the Company's shares, which is necessarily exacting with work covering legal, financial and technical due diligence, followed by a lengthy review process and dialogue with the relevant regulatory bodies. Needless to say the Covid-19 pandemic has also hindered progress.

The Directors remain committed to completing the Proposed Transaction as soon as possible and continue to believe that it is in the best interests of shareholders to do so.

Further updates will be provided through the Bould Opportunities website and announced as appropriate.

**Commenting Allan Syms, Chairman of Bould Opportunities, said:** "We appreciate the concerns and frustrations of shareholders, which are shared by the board and its advisers. However, we continue to work hard to complete the acquisition of a very exciting biotechnology business.

"2020 has been a difficult year for all as a result of the Covid-19 pandemic and has undoubtedly caused delays and created issues with the processes we have been going through. We remain focussed on creating shareholder value and I look forward to providing further updates in the New Year."

For further information:

**Bould Opportunities plc**  
Allan Syms, Chairman

c/o IFC Advisory

**IFC Advisory Limited** (Financial PR & IR)  
Tim Metcalfe  
Florence Chandler

+44(0)20 3934 6630  
bould@investor-focus.co.uk